Björn Engelbrekt Wahlin

15PUBLICATIONS
63CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTe mātai huingaira o te Māori (Māori genomics)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Apr 14, 2026
Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Prokop Vodička, Tarec C El-Galaly, Vit Prochazka

|Oct 24, 2024
Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma.

Catherine Thieblemont, Björn E Wahlin, Leyla Mohseninejad

|Jun 19, 2024
Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population-based study.

Tove Wästerlid, Caroline E Dietrich, Anna Oksanen

|Aug 21, 2023
Splenic marginal zone lymphoma in Sweden 2000-2020: Increasing rituximab use and better survival in the elderly.

Henna-Riikka Junlén, Kristina Sonnevi, Ola Lindén

|Jul 21, 2023
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.

Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa

Pageof 3

Frequent Collaborators

2 joint publications

Sara Harrysson

2 joint publications

Eliza A Hawkes

2 joint publications

Per-Ola Andersson

2 joint publications

Caroline E Dietrich